Clinical Trial Update: Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma [Phase 2]

View source ↗

Summary

A Phase 2 safety study of Ragweed-SPIRE in subjects with ragweed allergies and asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Seasonal Allergic Rhinitis

Drugs mentioned

• Ragweed-SPIRE

Snippet

Sponsor: Circassia Limited | Conditions: Seasonal Allergic Rhinitis, Asthma | Phase 2 | Status: COMPLETED